Clinical Trial Update: A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]

View source ↗

Summary

An adaptive-design Phase 3 trial is evaluating the efficacy and safety of TDI01 suspension in idiopathic pulmonary fibrosis. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• TDI01 suspension (TDI01)

Snippet

Sponsor: Beijing Tide Pharmaceutical Co., Ltd | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Status: RECRUITING